Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
354.5 EUR | -1.39% | -0.42% | -1.39% |
May. 03 | VIRBAC : Virbac remains an attractive animal healthcare play | |
Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.39% | 3.27B | B- | ||
-11.83% | 79.26B | B+ | ||
+15.37% | 8.39B | B- | ||
+28.00% | 3.74B | B- | ||
+21.28% | 1.69B | - | ||
-3.25% | 1.56B | B | ||
-18.63% | 1.29B | C- | ||
-1.17% | 1.28B | - | ||
-6.77% | 1.14B | - | ||
+2.26% | 1.06B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VIRP Stock
- Ratings Virbac